Communique from extraordinary general meeting in NeoDynamics AB (publ)

The extraordinary general meeting in NeoDynamics AB (publ) (the “Company”) was held on 25 February 2022 at the Company’s premises at Lejonvägen 14, Lidingö whereby the shareholders primarily resolved on the following matters.

The general meeting resolved in accordance with the Board of Director’s proposal on a new issue of shares with preferential rights for existing shareholders. The resolution increases the Company’s share capital with no more than SEK 6,025,059.20 by an issue of no more than 60,250,592 shares. The right to subscribe for shares shall, with preferential rights for existing shareholders, be granted to those who, on the record date of the share issue, are registered as shareholders in the Company.

Finally, the general meeting resolved in accordance with the Board of Director’s proposal to establish a warrant-based incentive scheme intended for the Company’s and its subsidiaries’ employees and other key persons. Within the framework of the scheme, participants who are employed by the Company or a subsidiary of the Company are offered a possibility to receive a bonus, provided that the participant remains an employee of the Company or a subsidiary of the Company at the termination term of the warrants, and that the participant exercises his/her warrants for subscription of shares.

The content of the resolutions is stated in the notice convening the general meeting.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

About NeoDynamics

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients.